A5042086094- Dermatology and Skin Diseases
- Cutaneous Melanoma Detection and Management
- Allergic Rhinitis and Sensitization
- Skin and Cellular Biology Research
- Autoimmune Bullous Skin Diseases
- Contact Dermatitis and Allergies
- AI in cancer detection
- Telemedicine and Telehealth Implementation
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Nonmelanoma Skin Cancer Studies
- Urticaria and Related Conditions
- Dermatological and Skeletal Disorders
- Acne and Rosacea Treatments and Effects
- COVID-19 and healthcare impacts
- Systemic Sclerosis and Related Diseases
- Pharmacological Effects of Natural Compounds
- Social Media in Health Education
- Herpesvirus Infections and Treatments
- Transgenic Plants and Applications
- Dermatological and COVID-19 studies
- Silk-based biomaterials and applications
- Stress Responses and Cortisol
- Wnt/β-catenin signaling in development and cancer
- Cancer and Skin Lesions
Stanford University
2016-2025
Palo Alto University
2022-2024
Stanford Medicine
2018-2023
Stanford Cancer Institute
2019
Columbia University Irving Medical Center
2014
University of California, Irvine
2014
Massachusetts General Hospital
2013
Angiogenesis Foundation
2011
University of Cambridge
2009
Texas Tech University
2005
An estimated 3 billion people lack access to dermatological care globally. Artificial intelligence (AI) may aid in triaging skin diseases and identifying malignancies. However, most AI models have not been assessed on images of diverse tones or uncommon diseases. Thus, we created the Diverse Dermatology Images (DDI) dataset-the first publicly available, expertly curated, pathologically confirmed image dataset with tones. We show that state-of-the-art dermatology exhibit substantial...
Primary results from the Measure Up 1 and 2 studies demonstrated upadacitinib efficacy safety through 16 weeks in patients with atopic dermatitis. Longer-term outcomes remain unknown.To evaluate long-term (52 weeks) of treatment dermatitis.Measure are ongoing double-blind, placebo-controlled, replicate phase 3 randomized clinical trials that include adults adolescents moderate to severe dermatitis at 151 154 centers, respectively. Cutoffs for this analysis were December 21, 2020 (Measure 1),...
BACKGROUND. Recessive dystrophic epidermolysis bullosa (RDEB) patients have mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they marked skin fragility blistering. This single-center phase 1/2a open-label study evaluated long-term efficacy, safety, patient-reported outcomes RDEB treated with gene-corrected autologous cell therapy.
Between 2000 and 2050, the number of new cancer patients diagnosed annually is expected to double, with an accompanying increase in treatment costs more than $80 billion over just next decade. Efficacious strategies for prevention will therefore be vital improving patients' quality life reducing healthcare costs. Judah Folkman first proposed antiangiogenesis as a strategy preventing dormant microtumors from progressing invasive cancer. Although antiangiogenic drugs are now available many...
Significance Timely detection of microscopic tumors is utmost importance in cancer diagnostics. We show that desorption electrospray ionization mass spectrometry imaging (DESI-MSI) can successfully locate aggregates a common skin cancer, basal cell carcinoma (BCC), and distinguish them from adjacent normal skin. DESI-MSI unveils an altered chemical profile BCC region, including lipids metabolites, does not rely on visual identification histopathologic features. processed specimens 86 Mohs...
The importance of reactive trajectories straying far from the minimum energy path is demonstrated for bimolecular reaction H + HBr --> H2(v', j') Br at 53 kcal/mol collision energy. Product quantum state distributions are measured and calculated using quasi-classical trajectory technique, calculations indicate that highly internally excited H2 products result indirect with bent transition states. A general argument made suggesting internal exceeding a kinematic constraint can, in general, be...
Itch is the most common skin disorder in elderly and frequently diminishes quality of life this population. The high prevalence pruritus patients attributed part to decline normal physiology advanced aging skin, reflects poor hydration, impaired barrier, altered neural function, all ultimately contributing inflammation pruritus. As population continues grow, practitioners need be aware how evaluate manage pruritus, recognizing conditions itch as well challenges treatment group. Ultimately,...
Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity impaired quality life (QoL). The Dupilumab Effect on AD Patients (DUPISTAD) phase IV randomized double-blinded placebo-controlled study evaluated the impact dupilumab treatment sleep other patient- physician-reported outcomes. Adults with moderate-to-severe were 2 : 1 to 300 mg once every weeks (q2w) or placebo for 12 weeks; concomitant topical...
Telemedicine use accelerated during the COVID-19 pandemic, and skin conditions were a common case. However, many images submitted may be of insufficient quality for making clinical determination.
This cross-sectional study uses data from the 2014-2018 National Health Interview Survey to assess whether there is an association between parental e-cigarette use and atopic dermatitis in children.
BackgroundChronic pruritus causes major morbidity in epidermolysis bullosa (EB). The substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-related pruritus.ObjectiveTo evaluate the safety and efficacy of oral NK1 antagonist serlopitant moderate-severe EB.MethodsThe study randomized 14 patients to or placebo 8 weeks, followed by 4-week washout optional open-label extension. primary end point was change itch as measured Numeric Rating Scale. Secondary points...
Abstract Sporadic human basal cell carcinomas (BCC) are generally well managed with current surgical modalities. However, in the subset of high-risk patients predisposed to developing large numbers BCCs, there is an unmet need for effective, low-morbidity chemoprevention. This population includes fair-skinned extensive sun exposure and those genodermatoses such as nevus (Gorlin) syndrome (BCNS). Tazarotene (Tazorac, Allergan) a topical retinoid relative specificity RAR-β RAR-γ receptors. We...
Abstract Background Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating blistering genodermatosis caused by mutations in the COL7A1 gene, which encodes for type VII collagen and necessary dermal-epidermal adhesion integrity. Disease manifestations include severe debilitating wounds, aggressive squamous cell carcinomas, premature death; however, there are currently no approved therapies. This Phase 1/2a, open-label study evaluated long-term efficacy safety of...
Dupilumab, the first monoclonal antibody approved by US Food and Drug Administration for treatment of moderate-to-severe atopic dermatitis (AD), inhibits interleukin (IL)-4 IL-13 via blockade IL-4Ra, inhibiting helper T cell (Th)2 signaling. Allergic contact (ACD) has a complex dynamic pathophysiology, in which at least 1 or more Th1, Th2, Th17/22 pathways may mediate reactions. Patients with AD are risk ACD. Here we present patient ACD who was patch tested before starting dupilumab during therapy.
Immunotherapy with immune checkpoint inhibitors that target the programmed cell-death receptor 1 (PD-1) is increasingly used for patients advanced or metastatic melanoma, non–small cell lung cancer, renal carcinoma, Hodgkin lymphoma, and urothelial carcinoma. Cutaneous adverse events occur during treatment these agents include pruritus, vitiligo, lichenoid dermatitis, psoriasiform and, more recently, bullous pemphigoid other autoimmune blistering disease.1-8 Interestingly, radiation therapy...
Dupilumab is a monoclonal antibody targeting interleukin-4 and interleukin-13 for the treatment of moderate-to-severe atopic dermatitis.1 We report case occupational irritant hand dermatitis in nonatopic individual that improved on dupilumab.
Recently, the skin manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have emerged, with reports and series documenting petechial eruptions, transient livedo reticularis, erythematous rashes, urticaria, primary varicella-like like presentations, pernio-like eruption.1-5 The eruption, colloquially termed COVID toes, appears associated an otherwise asymptomatic or mildly symptomatic disease course.4,6,7